Former GSK vaccine head Slaoui to lead federal 'Warp Speed' project: reports

Medicxi partner Moncef Slaoui
After leaving GlaxoSmithKline in 2017, Moncef Slaoui joined venture capitalist firm Medicxi as a partner. (Medixci)

The U.S. government's “Operation Warp Speed” aims to deliver a coronavirus vaccine to Americans by the end of the year, drawing on top minds in pharma, government and academia to do it. And now it has an experienced Big Pharma executive leading the charge.

The Trump administration has tapped former GlaxoSmithKline vaccine head Moncef Slaoui to lead the project, which incorporates the Department of Health and Human Services, the Department of Defense and other agencies to advance promising vaccines against COVID-19, according to reports. Already in the race to create a COVID-19 vaccine, programs from Pfizer, Johnson & Johnson, Sanofi, AstraZeneca and Moderna—where Slaoui now serves as a board member—have generated significant interest as they race ahead.

At a Senate hearing earlier this week, FDA Commissioner Stephen Hahn said the Warp Speed project deploys an “all of government” approach to developing and launching a promising COVID-19 vaccine. Officials are working through supply chain considerations as well as R&D to prepare for a massive vaccine rollout. 

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

Slaoui had a nearly 30-year run at GSK, joining in 1988 and leaving in 2017. He was a director for more than 10 years and also served as R&D head during his time at the drugmaker.  

RELATED: More exec turnover at GSK: Vax chief Slaoui to follow CEO Witty out the door next year 

After leaving GSK, Slaoui became a biopharma venture capitalist and joined the board of Moderna and other companies. He also joined life sciences investment firm Medicxi as a partner. With the Warp Speed appointment, he’s set to leave the Moderna and other boards, a source told Bloomberg. Shortly after the news broke, patient advocates such as the organization Public Citizen raised concerns about potential conflicts of interest.

Along with Slaoui, President Donald Trump has tapped four-star General Gustave Perna to help lead the program, according to reports. Slaoui is leading in a volunteer capacity, according to the Associated Press.

Operation Warp Speed first made headlines late last month with a report from Bloomberg detailing the effort spanning numerous government agencies and the military. At the time, the group reportedly aimed to deliver 100 million COVID-19 vaccine doses by the end of the year. But the Associated Press now cites a goal of 300 million. 

RELATED: 'Operation Warp Speed' aims to deliver a COVID-19 vaccine by year-end: Bloomberg 

Also at the Senate hearing this week, National Institute of Allergy and Infectious Diseases chief Anthony Fauci, M.D., said he’s “cautiously optimistic” one or more COVID-19 vaccines in development could work. Asked whether drugs or vaccines will be available in time for students to return to schools this fall, he said that’s a “bridge too far.”

Even as Fauci and others express optimism on the R&D front, some experts believe current vaccine development timelines are unrealistic. SVB Leerink analyst Geoffrey Porges has said creating a vaccine within 12 to 18 months would be as tough as hitting a bull's-eye with darts from 24 feet on the first try.

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.